Home › Upcoming votes › Vivos Therapeutics, Inc.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in Vivos Therapeutics, Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | ELECTION OF DIRECTORS Director election |
Board | For | 6 nominees; support 88% to 94% |
| 2 | ADVISORY VOTE ON EXECUTIVE COMPENSATION Say on pay |
Board | For | — |
| 3 | ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION Say-on-pay frequency |
Board | 3 years | — |
| 4 | RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Auditor |
Board | For | 98% support |
| 5 | REVERSE STOCK SPLIT | Board | For | — |
| 6 | Approval under Nasdaq Listing Rules 5635(b) and 5635(d) of issuances of Common Stock upon conversion of the Series A Convertible | Board | For | — |
| 7 | NASDAQ RULE 5635(a) AND 5635(b) APPROVAL OF THE ISSUANCE OF COMMON STOCK UPON CONVERSION OF THE SERIES C CONVERTIBLE PREFERRED STOCK | Board | For | — |
| 8 | AMENDMENT TO THE 2024 OMNIBUS EQUITY INCENTIVE PLAN | Board | For | — |
| 9 | CONVERSION TO A NEVADA CORPORATION | Board | For | — |
| 10 | To approve one or more adjournments of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes Adjournment |
Board | For | — |
From Vivos Therapeutics, Inc.’s Form 8-K, filed November 4, 2025, for the meeting held November 4, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: R. Kirk Huntsman | 93% | — |
| Elect Director: Dr. Ralph Green | 90% | Elected |
| Elect Director: Anja Krammer | 92% | Elected |
| Elect Director: Mark Lindsay | 94% | Elected |
| Elect Director: Leonard Sokolow | 91% | Elected |
| Elect Director: Dr. Matthew Thompson | 88% | Elected |
| 2. Approval of the Amendment to the Company's 2024 Omnibus Equity Incentive Plan Approved and adopted the Amendment to the 2024 Plan | 83% | — |
| 3. Ratification of the appointment of independent registered public accounting firm Appointment by the Company's audit committee of Baker Ti | 98% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.